Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

The In Vitro Anti-Cancer Activities of 17βH-Neriifolin Isolated from Cerbera odollam and its Binding Activity on Na+, K+-ATPase.

Yunos NM, Osman A, Jauri MH, Sallehudin NJ, Mutalip SSM.

Curr Pharm Biotechnol. 2020;21(1):37-44. doi: 10.2174/1389201020666190917154850.

PMID:
31530258
2.

PRactice of VENTilation in Middle-Income Countries (PRoVENT-iMIC): rationale and protocol for a prospective international multicentre observational study in intensive care units in Asia.

Pisani L, Algera AG, Serpa Neto A, Ahsan A, Beane A, Chittawatanarat K, Faiz A, Haniffa R, Hashemian R, Hashmi M, Imad HA, Indraratna K, Iyer S, Kayastha G, Krishna B, Moosa H, Nadjm B, Pattnaik R, Sampath S, Thwaites L, Tun NN, Yunos NM, Grasso S, Paulus F, de Abreu MG, Pelosi P, Dondorp AM, Schultz MJ; PRoVENT–iMIC investigators, MORU and the PROVE network.

BMJ Open. 2018 Apr 28;8(4):e020841. doi: 10.1136/bmjopen-2017-020841.

3.

Renal effects of an emergency department chloride-restrictive intravenous fluid strategy in patients admitted to hospital for more than 48 hours.

Yunos NM, Bellomo R, Taylor DM, Judkins S, Kerr F, Sutcliffe H, Hegarty C, Bailey M.

Emerg Med Australas. 2017 Dec;29(6):643-649. doi: 10.1111/1742-6723.12821. Epub 2017 Jun 8.

PMID:
28597505
4.

Chloride-liberal vs. chloride-restrictive intravenous fluid administration and acute kidney injury: an extended analysis.

Yunos NM, Bellomo R, Glassford N, Sutcliffe H, Lam Q, Bailey M.

Intensive Care Med. 2015 Feb;41(2):257-64. doi: 10.1007/s00134-014-3593-0. Epub 2014 Dec 18.

PMID:
25518951
5.

Mechanisms of action of 17βH-neriifolin on its anticancer effect in SKOV-3 ovarian cancer cell line.

Mutalip SS, Yunos NM, Abdul-Rahman PS, Jauri MH, Osman A, Adenan MI.

Anticancer Res. 2014 Aug;34(8):4141-51.

PMID:
25075041
6.

Anti-proliferative and pro-apoptotic effects from sequenced combinations of andrographolide and cisplatin on ovarian cancer cell lines.

Yunos NM, Mutalip SS, Jauri MH, Yu JQ, Huq F.

Anticancer Res. 2013 Oct;33(10):4365-71.

PMID:
24123004
7.

Chloride-restrictive fluid administration and incidence of acute kidney injury--reply.

Yunos NM, Bellomo R, Bailey M.

JAMA. 2013 Feb 13;309(6):543-4. doi: 10.1001/jama.2012.171514. No abstract available.

PMID:
23403667
8.

Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults.

Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M.

JAMA. 2012 Oct 17;308(15):1566-72. doi: 10.1001/jama.2012.13356.

PMID:
23073953
9.

The association between early arterial oxygenation and mortality in ventilated patients with acute ischaemic stroke.

Young P, Beasley R, Bailey M, Bellomo R, Eastwood GM, Nichol A, Pilcher DV, Yunos NM, Egi M, Hart GK, Reade MC, Cooper DJ; Study of Oxygen in Critical Care (SOCC) Group.

Crit Care Resusc. 2012 Mar;14(1):14-9.

PMID:
22404056
10.

Synergism from the combination of oxaliplatin with selected phytochemicals in human ovarian cancer cell lines.

Yunos NM, Beale P, Yu JQ, Huq F.

Anticancer Res. 2011 Dec;31(12):4283-9.

PMID:
22199293
11.

The biochemical effects of restricting chloride-rich fluids in intensive care.

Yunos NM, Kim IB, Bellomo R, Bailey M, Ho L, Story D, Gutteridge GA, Hart GK.

Crit Care Med. 2011 Nov;39(11):2419-24. doi: 10.1097/CCM.0b013e31822571e5.

PMID:
21705897
12.
13.

Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines.

Yunos NM, Beale P, Yu JQ, Strain D, Huq F.

Anticancer Res. 2010 Oct;30(10):4025-37.

PMID:
21036717
14.

Bench-to-bedside review: Chloride in critical illness.

Yunos NM, Bellomo R, Story D, Kellum J.

Crit Care. 2010;14(4):226. doi: 10.1186/cc9052. Epub 2010 Jul 8. Review.

Supplemental Content

Loading ...
Support Center